DataMeds AI, Inc. completed its acquisition of Helomics Corp. from Axe Compute Inc. in a transaction valued at $1.5 million and structured through common shares and an acquisition note. The deal includes Helomics’ CLIA/CAP-certified clinical laboratory, equipment and $1.5 million in cash, with no third-party debt. DataMeds said the acquisition expands its healthcare business into oncology, complementing services focused on GLP-1 agonist side effects and Long COVID. Shares rose 66.04% to $2.68 in premarket trading before closing the regular session up 87.20% at $1.62, according to Benzinga Pro data.